ProQR to Virtual Webcast Analysis


LEIDEN, The Netherlands and CAMBRIDGE, Mass., November 11, 2021 (GLOBE NEWSWIRE) – ProQR Therapeutics NV (PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual analysts event on November 18, 2021, from 12:00 p.m. to 2:00 p.m. ET to highlight its clinical stage pipeline programs and the Axiomer® RNA editing platform.

ProQR’s Leadership to Highlight Key Advances in Its Clinical-Stage Pipeline, Including Phase 1/2 Data Overview sepofarsen extension study. The Company will also highlight the sepofarsen program more broadly, summarizing program data to date, sharing a patient’s perspective from the phase 1/2 trial, and examining phase 2/3. Enlighten test design and assumptions. QR-421a, QR-1123, QR-504a and RNA editing platform technologies will also be presented.

Program

Welcome Sarah Kiely, Vice President of Public Relations and Corporate Communications
Vision and strategy Daniel A. de Boer, Managing Director
Clinical programs Aniz Girach, MD, Chief Medical Officer
RNA Toolkit Gérard Platenburg, Director of Innovation
Questions and answers led by Smital Shah, Commercial and Financial Director

Webcast information

Attendees can pre-register for the live stream and access the archived webcast through this webcast link or from the “Investors and Media” section of the ProQR website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days after the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of serious rare genetic diseases such as congenital Leber 10 amaurosis, Usher syndrome and retinitis pigmentosa. Based on our proprietary RNA repair platform technologies, we are developing our pipeline with patients and their loved ones in mind.
Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by words such as “anticipate”, “believe”, “might”, “estimate”, “expect”, “objective”, “Intend”, “look forward to”, “may”, “plan”, “potential”, “anticipate”, “plan”, “should”, “will”, “would” and similar expressions. These forward-looking statements include, without limitation, statements regarding the analyst’s event. Forward-looking statements are based on the beliefs and assumptions of management and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for a number of reasons, including, without limitation, risks, uncertainties and other factors in our documents filed with the Securities and Exchange Commission, including including certain sections of our annual report filed on Form 20-F. In view of these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, unless required by law. .

ProQR Therapeutics SA

Investor contact:
Sarah kiely
ProQR Therapeutics SA
T: +1 617 599 6228
[email protected]
Where
Hans vitzthum
LifeSci Advisors
T: +1 617 430 7578
[email protected]

Media contact:
Cherilyn Cecchini, MD
LifeSci Communications
Phone. : +1 646 876 5196
[email protected]

ProQR-Therapeutics-NV-.png


Comments are closed.